Core Insights - The latest real-world study data on NEFECON® (Budesonide delayed-release capsules) presented at the 2025 IIgANN conference demonstrates significant clinical benefits for IgA nephropathy patients through long-term targeted therapy [1][3][4] Group 1: Study Findings - A retrospective study evaluated the efficacy and safety of 12 months of Budesonide treatment in IgA nephropathy patients, showing a reduction in 24-hour urinary protein from 1016 mg to 114 mg, significantly lower than the control group [2][3] - The eGFR slope in the Budesonide group was significantly better than the control group, with rates of 5.4 ml/min/1.73m²/year versus -3.4 ml/min/1.73m²/year [2][3] - No serious infections occurred in the Budesonide group, indicating a favorable safety profile compared to traditional treatments [2][3] Group 2: Clinical Implications - The treatment of IgA nephropathy should focus on short-term proteinuria control and long-term kidney function stability, as emphasized in the 2025 guidelines [3] - Budesonide is the only approved targeted therapy for IgA nephropathy, recommended by both domestic and international guidelines for its mechanism of reducing pathogenic IgA production [3][4] - The study reinforces Budesonide's role as a cornerstone treatment for IgA nephropathy, highlighting the necessity of long-term targeted therapy in disease management [3][4] Group 3: Market Context - There are over 5 million IgA nephropathy patients in China, with more than 100,000 new cases diagnosed annually, indicating a significant unmet clinical need [4] - NEFECON® is the first and only targeted therapy for IgA nephropathy approved in China, the US, and Europe, not limited by proteinuria levels, thus reshaping treatment pathways for patients [4]
IIgANN 2025：耐赋康®最新真实世界研究证实长期对因治疗持续展现良好有效性与安全性